Skip to content
Screener

Ardelyx ARDX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Amgen logo
AmgenAMGN
$95.64B+8.8%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$24.5B-7.3%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$285.13M-16.9%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$97.71M+16.3%
XER
Xeris Biopharma Holdings, Inc.XERS
$411.91M+23.1%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$996.75M-23.4%
Enterprise value$1.16B-18.5%
P/S2.2×-1.2×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock, $0.0001 par value per share; 500,000,000 shares authorized; 249,147,061 and 244,351,501 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively2524
Additional paid-in capital1,150,4461,113,666
Accumulated deficit(1,001,265)(946,939)
Accumulated other comprehensive (loss) income(193)198
Total stockholders’ equity149,013166,949
Total liabilities and stockholders’ equity$575,894$501,604

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's total liabilities & equity?
Ardelyx (ARDX) reported total liabilities & equity of $575.89M in Q2 2026.
How has Ardelyx's total liabilities & equity changed year-over-year?
Ardelyx's total liabilities & equity increased by 23.4% year-over-year, from $466.77M to $575.89M.
What is the long-term trend for Ardelyx's total liabilities & equity?
Over 5 years (2020 to 2025), Ardelyx's total liabilities & equity has grown at a 20.0% compound annual growth rate (CAGR), from $201.56M to $501.6M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Ardelyx's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude